Sinovac"s PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
来源:美通社
11月18日 00:31

全文模式(共6页)
　　BEIJING, Nov. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company"s H1N1 vaccine. The population has been expanded to include people over 60 years old. The shelf life for PANFLU.1 was extended to one year from six months.

下页余下全文
[1] 2 3 4 ...6 至页go1/6
返回上级
上篇：Autoliv 将收购Delphi北美被动保护乘客事业资产
下篇：Netflix创52周新高後走势震荡
心情栈
(0) (0) (0) (0)
(0) (0) (0) (0)
返回美股新闻快报 <美股 <财经 <首页

 不想错过凤凰独家新闻点这里
 返回手机凤凰网